Clinical Operations in Oncology Trials East Coast 2023

Discover effective strategies for oncology trial operations to ensure trials run smoothly and within budget.

  • Boston, MA, United States
  • Complimentary
close

Why attend?

WHAT TO EXPECT FOR 2023?

Clinical Operations in Oncology is the meeting place for leading pharmaceutical companies and biotechnology institutes. Discover how to excel in oncology operations and clinical supply strategy as well as form key connections for long-term success for your clinical trial.

200+

Attendees

20+

Exhibitors

15+

Speakers

85%

Attendees at Director+ level

200+

Attendees

20+

Exhibitors

15+

Speakers

85%

Attendees at Director+ level

See What It's All About

2022 Agenda

  • 19 Jul 2022
  • 20 Jul 2022
Expand All

8 AM

Registration and refreshments

8:50 AM

Chairperson’s opening remarks

Speakers

9 AM

OPENING KEYNOTE: Disruption in Oncology trials: new technology and themes in 2022

During this opening keynote, Len Rosenberg will be setting the scene for oncology trials in 2022: what’s new, and what’s changed? Hear Len’s thoughts on topics including:

  • Are sponsors fully embracing change and technology?
  • Decentralized approaches for oncology trials: what works, and what doesn’t?
  • Beyond the obvious: where are opportunities for innovation being overlooked?

Speakers

9:30 AM

AI Powered Enrollment Forecasting and Real Time Industry Insights

How well are you able to forecast enrollment and track external factors that can impact the performance of your ongoing study?
In this session you will learn how Medidata Acorn AI’s Intelligent Trials solution leverages performance data from 27,000+ clinical trials and 1M+ study sites to:

  • Use predictive models to significantly enhance enrollment forecasting and reforecasting, enabling more proactive responses
  • Keep trials on track with real time monitoring of performance against similar trials and changing industry conditions
  • Include industry patient diversity benchmarks within specific indications to drive real improvements in clinical trial recruitment

Speakers

10 AM

KEYNOTE: Participating in a clinical study as a cancer patient

  • An overview of participating in a clinical trial from a patient’s perspective: what do trial sponsors overlook?
  • Understanding the experience of enrolling in a trial as a patient, from becoming aware of the study through to clinic visits
  • The importance of regular communication with patients
  • Making participation as easy as possible for your patients: what do patients really want?

Speakers

10:30 AM

Flexible by Design: Tools to Manage Uncertainty & Complexity in Early Phase Oncology Trials

  • Examine common challenges in early phase oncology trials that can be mitigated with technology tools
  • Explore functionality that can help manage the uncertainty in trial duration, treatment variability and protocol amendments
  • Discuss how an early phase oncology trial case study leveraged IRT functionality to address the protocol complexities

Speakers

11 AM

Morning refreshments and networking

11:30 AM

PANEL: Reducing the burden of clinical trials on oncology patients

  • Considering your patient during the study design phase: working closely with patients and advocacy groups in order to achieve this
  • Understanding patient accessibility needs: are decentralized and hybrid approaches the way forward?
  • Ensuring potential patient participants are aware of your trial: maximizing the reach of your recruitment campaigns
  • Making “no decision about the patient without the patient”: what this means for your clinical trial

Speakers

12:15 PM

Building Effective Site Relationships: A Solid Case

Julie Martin, CEO of Scimega Research builds a solid case for effective site relationship how to’s for the long term to ensure the best possible outcomes for oncology clinical trial sponsors and the cancer patients participating in their cutting-edge trials.

Key insights include strategies to:

  • Expedite suitable site identification using hard data sets
  • Optimize site engagement to attain maximum effectiveness for quality, timely data entry and query resolution
  • Address site staff turnover to effectively mitigate risk for patient safety
  • Best practices to meet and surpass enrollment targets

Speakers

12:45 PM

Growing an Early Development pipeline by 300% in 2 years, leveraging T and NK cell immunology, maintaining innovation and a collaborative culture

  • An overview of Sanofi Genzyme’s oncology pipeline and understanding its specific operational requirements
  • Facilitating cross-team support and ensuring resource optimization
  • Ensuring data safety and efficacy

Speakers

1:15 PM

Lunch and networking

2:15 PM

Recruitment and retention strategies in clinical trials

  • Selection of regions/sites to support enrolment targets
  • Methods of engaging patients for enhanced recruitment
  • Retention options and impact of availability of options based on global footprint of trials

Speakers

2:45 PM

Integrative approach to biomarker-driven patient enrolment in oncology and rare diseases clinical research

  • Oncology clinical research is evolving towards personalized treatment of patients in niche patient populations
  • New biological targets frequently have a low level of prevalence, requiring innovative approaches to patient identification
  • Precision for Medicine has developed a comprehensive and integrated solution to this challenge working across clinical solutions, biospecimens and data and EHR interrogation to implement enhanced recruitment plans

Speakers

3:15 PM

Building confidence in wearable intelligence and digital biomarkers as novel endpoints in oncology trials

  • What is the value and regulatory pathway of measurements collected remotely using digital technologies?
  • How to use real-time analytics and artificial intelligence (AI) to improve treatment outcomes and predict AEs?
  • What does it take to unlock the power of continuous patient monitoring in real-world settings?

Speakers

3:45 PM

Data-Driven Operations and Oversight with elluminate

Operational oversight within outsourced models has become increasingly complex for teams who are tasked with managing trials amid a rapidly changing landscape of partners, technologies, and global regulations. The elluminate Clinical Data Cloud provides one source of truth for clinical and operational data to manage trials across sources. Learn how elluminate delivers:

  • Operational analytics including enrolment, protocol compliance and safety
  • Risk-based analyses and insights with elluminate RBQM
  • Operation knowledge for data-driven development with elluminate CTMS
  • Centralised issue management across roles in operations, data and medical review
  • Sample tracking, data forecasting and financial performance indicators

Speakers

4 PM

Afternoon refreshments and networking

4:30 PM

CASE STUDY: Targeted personalized cancer therapy: the holy grail of cancer treatment

  • An overview of Andarix’s technology to target lung and pancreatic cancer
  • Developing personalized cancer treatments: challenges and opportunities
  • Shipping products from lab to patient: what is required?
  • Results from Phase 1 studies and plans for Phase 2
  • Identifying national and international partners to make trials a success

5 PM

Strategies for successful oncology recurrence trials

This presentation will address successful strategies for oncology recurrence trials including a review of operational and read recommendations to help you improve efficiency and quality for your recurrence studies. The speaker will discuss:

  • Imaging in the context of surveillance;
  • Other procedures for detection of recurrence not discussed;
  • Clinical trials design, including disease-free status;
  • Central imaging evaluation including: establishing disease free status, detection of recurrence and characterization of recurrence; and
  • Operational considerations

Speakers

5:30 PM

Implementing a risk-based data strategy in oncology trials

  • Outlining smart guide lines for a risk-based data strategy
  • Defining and ensuring smart data collection

Speakers

5:30 PM

Chairperson’s closing remarks

END OF DAY 1 AND NETWORKING DRINKS

8:15 AM

Registration and refreshments

8:50 AM

Chairperson’s opening remarks

Speakers

9 AM

PROBLEM-SOLVING ROUNDTABLE DISCUSSIONS

During the roundtable discussion session, the conference hall will be divided into three ‘zones’. Delegates can choose which zone they would like to join. Each zone will be led by a table moderator and will focus on a different challenge within clinical operations in oncology trials. After 45 minutes, delegates will have the opportunity to swap and choose a different table, and each roundtable will run twice.

ROUNDTABLE 1: Funding your oncology study as a small to medium sized biotech: getting buy in from investors

ROUNDTABLE 2: Challenges and opportunities of decentralization in oncology studies

ROUNDTABLE 3: Putting your patient first: making your oncology study as patient-centric as possible

Yolanda Wan, Vice President, Clinical Operations, Accutar

ROUNDTABLE 4: Considerations and best practice for maintaining a strong site-sponsor relationship

Diana Hummel, Associate Director, Clinical Operations, Relay Therapeutics

Speakers

10:30 AM

Morning refreshments and networking

11 AM

PANEL: Incorporating decentralized approaches into your oncology trial: what works, and what doesn’t?

  • Why has oncology been slower to adopt decentralization in clinical trials?
  • What elements of decentralization could be incorporated into oncology?
  • Understanding your patient: is decentralization the most desirable approach for your patient?
  • Regulatory considerations when running a decentralized trial in oncology
  • Decentralization as a method of increasing recruitment and improving retention: does this work in oncology?

Speakers

11:30 AM

Image assessments in early phase oncology trials and imaging risks that can affect your trial

Imaging endpoints are often used to support go/no-go decision making in early phase trials. This is also a critical time to determine the development strategy for later study phases. Many clinical development teams find themselves questioning:

  • What imaging biomarkers should we target?
  • What endpoints and criteria best suit the compound?
  • Are central reads necessary for all subjects?
  • Should we just collect and hold images? if so, what decision tree do we use to pull the trigger on central reads?
  • What supporting clinical data should be collected?
  • What types of radiology support do we need?

 

Speakers

12 PM

STUDY RESULTS: Clinical research professionals and the shift to remote work during the COVID-19 pandemic

  • An overview of Tufts CSDD’s global study on remote working in clinical research, in collaboration with the Bill and Melinda Gates Medical Research Institute
  • The impact of remote working on productivity in the execution of clinical research
  • General preparedness and responsiveness of research organizations
  • Assessing the overall positive and negative effects of working remotely for clinical research professionals

 

 

Speakers

12:30 PM

Lunch and networking

1:30 PM

FIRESIDE CHAT: Handling the long term impact of COVID on oncology clinical trials

  • With new variants and ever changing restrictions, what COVID-related considerations should you take into account when designing an oncology trial?
  • Running a clinical trial with social distancing in place: what measures are likely to be long term?
  • The importance of working closely with CROs, vendors, sites and patients to mitigate the impact of COVID on oncology trials
  • Risk management and how pandemic-handling measures will affect processes in the long term

Speakers

2 PM

Advancing Technology in Oncology Clinical Trials and What the Patients Want You to Know

  • Discussing recent insights in research on a global scale within the oncology community surrounding technology and decentralized trials preferences
  • What oncology patients want from their mobile technologies
  • Best practices and tactics for meaningful engagement within this patient population
  • Oncology patients’ preferences in the post-Covid era of decentralized trials

 

Speakers

2:30 PM

Afternoon refreshments and networking

3 PM

Clinical development landscape of immune-oncology agents

  • What are the most important industry trends in immuno-oncology (IO)?
  • What does the IO pipeline look like and what are the key targets?
  • What are some of the challenges in running trials for IO therapies?

Speakers

3:30 PM

Innovative Solutions for Today’s Clinical Trial Needs

  • Virtual Clinical Supply Model
  • Direct to Patient Capabilities
  • Global Clinical Supply Offering
  • Medical Procedures, services, and product reimbursement
  • Improve Site Feasibility and Remove Barriers

4 PM

Chairperson’s closing remarks

END OF CONFERENCE

2022 Speakers

Select a speaker to learn more

Back
JEFFREY DIPAOLO
Manager Oncology Medical Affairs, Clario

Jeffrey DiPaolo, MD is the Manager, Oncology Medical Affairs at Clario. He is board certified in Diagnostic Radiology and Neuroradiology with extensive experience in oncology. In his current role, Dr. DiPaolo focuses on trial read design and sales support for the Oncology Medical Affairs team. Previously, he was the Co-founding Partner of Open MRI of Wall (NJ) and Partner/Radiologist at PPRG (NJ). Dr. DiPaolo has specialized in diagnostic radiology, neuroradiology and radiology and holds an emeritus position at Ocean University Medical Center, part of Hackensack Meridian Health. Dr. DiPaolo was a Neuroradiology Fellow at the University of Michigan and received his medical degree from Sidney Kimmel Medical College at Thomas Jefferson University. He practiced for more than 20 years and has over 35 years of experience in the field of medicine.

Session Details:

Strategies for successful oncology recurrence trials

2023-07-11, 5:00 PM

View In Agenda
Next speaker
Back
JULIE MARTIN
Chief Executive Officer, Scimega

Julie Martin - CEO & co-Owner joined Scimega 9 years ago. Having worked for 2 other CROs before, her passion for Scimega’s business and team stems from knowing its expert oncology clinical development services add distinct value to industry stakeholders at a time when it’s needed most. As CEO, Julie’s vision is to secure the company’s long-term success by leveraging her in-depth industry expertise & business acumen. She equates that success with setting a clear vision for the organization’s continued sense of purpose. Her leadership & collaboration with the managing Board of Directors combined ensure the business excellence upon which Scimega has built its reputation. Julie plays a vital role in promoting Scimega’s expertise and showcasing Canada’s attributes as a formidable partner in global oncology drug development.

Session Details:

Building Effective Site Relationships: A Solid Case

2023-07-11, 12:15 PM

View In Agenda
Next speaker
Back
AMIR LAHAV
Digital Healthcare Innovation,

Session Details:

Building confidence in wearable intelligence and digital biomarkers as novel endpoints in oncology trials

2023-07-11, 3:15 PM

View In Agenda
Next speaker
Back
ROB HUMMEL
Chief Operating Officer , Suvoda

As co-founder and Chief Operating Officer, Rob Hummel is responsible for global operations at Suvoda. His leadership is fundamental to the delivery of high-quality products, outstanding client services, and overall company growth. He maintains oversight of the sales and professional services teams worldwide and has led significant team growth while exceeding customer satisfaction targets year over year. Prior to Suvoda, Rob held leadership positions with NextDoc Corporation and Clarix/Phase Forward, where he was instrumental in delivering life sciences solutions for clients ranging from small biotechnology firms to large, global pharmaceutical companies and CROs. Rob holds a B.S. in biology from Lafayette College.

Session Details:

PANEL: Incorporating decentralized approaches into your oncology trial: what works, and what doesn’t?

2023-07-12, 11:00 AM

Session Details:

Flexible by Design: Tools to Manage Uncertainty & Complexity in Early Phase Oncology Trials

2023-07-11, 10:30 AM

View In Agenda
Next speaker
Back
DAWN KAMINSKI
Vice President, Business Development Operations, EClinical Solutions

Dawn has over 20 years of experience in the pharmaceutical industry. She have worked within every level of clinical data management, from Data Coordinator to Senior Director where she participated in or had oversight for more than 250 clinical trials. During her time in the industry, she has provided consultation to organizations on clinical trial conduct, best practices in Data Management and data capture as well as developed standardized libraries and templates to support the adoption of CDISC standards. She is an active member of SCDM as a GCDMP SME, course designer and webinar presenter as well as Co-Chair of the annual conference (2018-2021) and serves on the SCDM Board of Trustees. Dawn is involved as a member of the CDISC-CDASH core team, Diabetes sub-team, CDASH CFAST Expanded Leadership Team and former Co-Chair of the CRF Library project. Dawn currently holds the position of Vice President, BD Operations, where she supports business development as a Clinical Subject Matter Expert for both software and data services as well as overseeing the Proposals and Solution Consulting departments.

Session Details:

Data-Driven Operations and Oversight with elluminate

2023-07-11, 3:45 PM

View In Agenda
Next speaker
Back
Marina Escudero
VP of Clinical Operations, Leap Therapeutics

Session Details:

PANEL: Incorporating decentralized approaches into your oncology trial: what works, and what doesn’t?

2023-07-12, 11:00 AM

View In Agenda
Next speaker
Back
TAMIEKA HUNTER
Director Clinical Operations, Relay Therapeutics

Tamieka Lauz Hunter joined Relay Therapeutics 1.5 years ago. Having worked for a multitude of pharmaceutical, biotechnology and CRO organizations over 12 years with primary therapeutic expertise in clinical execution of oncology programs. Her passion lies in precision medicine and bringing novel therapeutic options to patients with unmet need. Tamieka acquired a MSHS: Clinical Research Administration at George Washington University School of Medicine.

Session Details:

PANEL: Reducing the burden of clinical trials on oncology patients

2023-07-11, 11:30 AM

Session Details:

Recruitment and retention strategies in clinical trials

2023-07-11, 2:15 PM

View In Agenda
Next speaker
Back
RICK PATT
Co-Founder And Principal, RadMD

Dr. Patt is Co-Founder and Principal in RadMD. He has a broad prior experience in medical imaging: this includes research and development of contrast agents: design and manage site and central reviews and trained reviewers for over 300 oncology trials; and has expertise in cardiovascular device, infectious disease, and pulmonary fibrosis trials. He has performed blinded reads and adjudications in a variety of trial types. He has held positions as both an academic and private practice radiologist. After his fellowship at Georgetown University and the National Institutes of Health (NIH), he served as Chief of Body MRI, then Director of MRI, at Georgetown University Medical Center, where he was both an investigator and blinded reader in numerous pharmaceutical and medical device clinical trials. He subsequently joined Berlex Labs as Associate Director, followed by Director of Medical Imaging Clinical Development. where he managed an experienced team in all phases of clinical development of radiological contrast agents. Dr. Patt also served as Medical Director for HealthHelp, a radiology management services organization. He founded Foresight Consulting, working with pharmaceutical and medical device companies on the utilization of medical imaging into clinical development programs. He has numerous publications, has served on an NCI Advisory Panel, is a reviewer for major radiology journals, and has been an invited lecturer across the US and Europe on the use of medical imaging in clinical trials.

Session Details:

Image assessments in early phase oncology trials and imaging risks that can affect your trial

2023-07-12, 11:30 AM

View In Agenda
Next speaker
Back
Maria Florez
M.A., Research Consultant, Tufts Center for the Study of Drug Development

Session Details:

STUDY RESULTS: Clinical research professionals and the shift to remote work during the COVID-19 pandemic

2023-07-12, 12:00 PM

View In Agenda
Next speaker
Back
CHRIS ADAMS
Founder & CEO, Andarix

Mr. Adams has been a founder or co-founder of life science and technology based companies in Massachusetts for the past several years. Mr. Adams has been instrumental in developing new proprietary therapeutic and medical device technologies and bringing the technologies to commercialization. The companies he has founded include, Compellis Pharmaceuticals, a developer of therapeutics to treat obesity and its co-morbidities, diabetes and hypertension and Mosaic Technologies, a venture backed MIT spin-out genomics company that developed patented technologies for genetic analysis and detection.
Chris is the holder of more than 20 issued US and international patents for medical devices and pharmaceuticals.

Next speaker
Back
Mary Jo Lamberti
Professor, Director, Tufts

Session Details:

STUDY RESULTS: Clinical research professionals and the shift to remote work during the COVID-19 pandemic

2023-07-12, 12:00 PM

View In Agenda
Next speaker
Back
LETICIA TARILONTE
Executive Director, Clinical Operations, Black Diamond Therapeutics

Leticia has over 20 years of industry experience managing several research projects and clinical studies in various roles. She started her career in Pharma at Biogen, working collaboratively in an integrated monoclonal antibody research team and then moving to development in clinical operations, where she managed numerous phase I-III clinical trials in diverse therapeutic areas including, gastroenterology, immunology, neurology, and neuropathic pain. She continued her career at Merck/EMD Serono where she served as a Clinical Research Scientist providing strategic and operational expertise in the planning and conduct of Phase I-III clinical studies in oncology and immuno-oncology, contributing to the BLA submission of BAVENCIO®, which led to the FDA accelerated approval in merkel cell carcinoma and in urothelial carcinoma. Later she served as a Chief of Staff to the Head of Development in Oncology, where she partnered with executive sponsors to identify and promote projects that are of strategic importance to the company and translating the function strategy into operational plans. In 2020 Leticia joined Black Diamond Therapeutics, a biotech company addressing the significant unmet need for novel precision oncology therapies for patients with genetically defined cancers. Leticia’s efforts have been widely recognized by promotion to Executive Director of Clinical Operations where she is responsible for ensuring that clinical stage programs achieve objectives within established timelines, budget, and quality standards, while fostering a highly collaborative culture and serving as a leadership role model. Leticia earned her Bachelor’s Degree in Biomedical Laboratory and Clinical Sciences from the School of Medicine at Boston University, followed by a Master’s Degree in Regulatory Affairs and Health Policy from the Massachusetts College of Pharmacy and Health Sciences in Boston.

Session Details:

FIRESIDE CHAT: Handling the long term impact of COVID on oncology clinical trials

2023-07-12, 1:30 PM

Session Details:

PANEL: Incorporating decentralized approaches into your oncology trial: what works, and what doesn’t?

2023-07-12, 11:00 AM

Session Details:

PANEL: Reducing the burden of clinical trials on oncology patients

2023-07-11, 11:30 AM

View In Agenda
Next speaker
Back
ROBERT BUKA
Director, Medidata Acorn AI Intelligent Trials, Medidata

Robert Buka is a Product Director for the Acorn AI Intelligent Trials portfolio. He leads Acorn's Study Feasibility product, which helps pharmaceutical sponsors and CROs use historical data and predictive algorithms to properly plan and execute their clinical trials to achieve study accrual targets. Robert has over 9 years of technology industry experience leading data science teams and delivering digital transformation projects. Robert studied Biology and Statistics at the University of Pennsylvania.

Session Details:

AI Powered Enrollment Forecasting and Real Time Industry Insights

2023-07-11, 9:30 AM

View In Agenda
Next speaker
Back
FATIMA SCIPIONE
Senior Vice President, Strategic Alliances And External Affairs, International Myeloma Foundation

Fatima is passionate about elevating the patient voice on a global scale. She believes that understanding patient experiences and challenges is essential to speeding up the development of life-changing medicines. Further, she advocates in support of patients gaining the skills, courage, and knowledge to navigate through a cancer diagnosis, to make informed decisions, and to ensure they can advocate for and achieve the best care possible. This fierce passion and commitment to putting the needs of patients first is evident in her decades-long career where she is recognized as an influential global advocate thought leader focused on patient centered research, policy, access, and regulatory impact. She has held multiple senior management positions in healthcare and is a respected member of the biopharma and cancer communities. Fatima has contributed to numerous publications in partnership with the advocacy community and key academic researchers to advance patient-centered care, as well as being included in the PharmaVOICE 100 in 2014 and receiving the Trailblazer Brand Champion Award from PM3670 in 2015

Session Details:

PANEL: Reducing the burden of clinical trials on oncology patients

2023-07-11, 11:30 AM

View In Agenda
Next speaker
Back
Matthew Dame
Director Clinical Data Management, X4 Pharamceuticals

Session Details:

Implementing a risk-based data strategy in oncology trials

2023-07-11, 5:30 PM

View In Agenda
Next speaker
Back
LEN ROSENBERG
Head Of Clinical Operations, BAML, LLC A Division Of The Leukemia & Lymphoma Society

Dr. Rosenberg is a 30 plus year executive with proven experience in driving operational excellence at all levels within the pharmaceutical, biotechnology, eclinical and contract research organization sectors. With his diverse background which includes executive management, clinical and regulatory operations, business development, eclinical technology solutions and new product/licensing evaluations, he brings tremendous hands on insights to optimizing the drug development cycle, from the early start-up stage to global product registration across many key therapeutic areas including CNS and oncology. Dr. Rosenberg is Managing Partner of eP2Consulting, Inc. since 2001. He also currently serves as Head, Clinical Operations at Beat AML, LLC, a division of The Leukemia & Lymphoma Society. Dr. Rosenberg received his Ph.D., from the Kellogg Pharmaceutical Clinical Scientist Program, University of Minnesota, College of Pharmacy and his Bachelor of Science, Pharmacy, from the Philadelphia College of Pharmacy and Science. Contact Information: 4 Quail Court, Mount Laurel, NJ 08054 (c: 609-923-9443)

Session Details:

Chairperson’s opening remarks

2023-07-12, 8:50 AM

Session Details:

Chairperson’s opening remarks

2023-07-11, 8:50 AM

Session Details:

OPENING KEYNOTE: Disruption in Oncology trials: new technology and themes in 2022

2023-07-11, 9:00 AM

View In Agenda
Next speaker
Back
MICHAEL BREEN
Associate Director, Infectious Disease, GlobalData Healthcare

Michael Breen, PhD, is the Senior Director of Infectious Diseases and Oncology at GlobalData in Boston. He has over eight years of experience in market analysis, business intelligence, and providing strategic insight for the pharmaceutical industry. Prior to his current role, he was a Senior Analyst for Decision Resources Group, where he gained extensive experience writing in-depth reports and developing forecasts for a variety of indications, including rare and infectious diseases and vaccines. Michael has a BA in biology and biochemistry from Hunter College, and a PhD in biochemistry from Boston University School of Medicine.

Session Details:

Clinical development landscape of immune-oncology agents

2023-07-12, 3:00 PM

View In Agenda
Next speaker
Back
CHRISTINA DIARCANGELO
Chief Executive Officer, Affinity Patient Advocacy

An entrepreneur and CEO with more than two decades of experience in the medical cannabis, biotechnology, pharmaceutical, nutraceutical, and medical device industries, Christina’s dedication to revolutionizing patient care is unprecedented. Through her roles as CEO, Spectral Analytics Precision Tele-Monitoring, Founder and CEO of Affinity Bio Partners, Board President and CEO of Affinity Patient Advocacy, and CEO & Co-Founder of AI Health Outcomes, Christina has been involved with revolutionary projects and global clinical studies that positively impact patients. As a clinical research pioneer, contracts negotiator, Opinion Columnist for CEO WorldBiz, and host of the I Am Christina DiArcangelo show, she has utilized the tools at her disposal to champion patient care and provide best-in-class patient advocacy services. For Christina, patient care comes first.

Session Details:

KEYNOTE: Participating in a clinical study as a cancer patient

2023-07-11, 10:00 AM

View In Agenda
Next speaker
Back
Diana Hummel
Associate Director, Clinical Operations, Relay Therapeutics

Session Details:

PROBLEM-SOLVING ROUNDTABLE DISCUSSIONS

2023-07-12, 9:00 AM

View In Agenda
Next speaker
Back
YOLANDA WAN
Vice President Of Clinical Operations,, Accutar

Yolanda is the Vice-President of Clinical Operations at Accutar Biotechnology. She brings along 17 years of experience in Clinical Development, with focus on both Clinical Operations and Clinical Project Management. Her areas of expertise include strategic operations planning at the compound-level; first-in-human study planning & adaptive execution in therapeutic areas of oncology and ophthalmology. Leadership with cross-functional teams has included the development and implementation of governance and operational strategy, optimizing processes and building dynamic teams to exceed business objectives. Prior to joining Accutar, she held various positions at Bayer in the US and a number of countries within Asia. This attributes to her extensive knowledge of bridging-strategy between the two continents.

Session Details:

PROBLEM-SOLVING ROUNDTABLE DISCUSSIONS

2023-07-12, 9:00 AM

View In Agenda
Next speaker
Back
GIOVANNI ABBADDESSA
VP, Head, Oncology Early Development, Sanofi Genzyme

Session Details:

Growing an Early Development pipeline by 300% in 2 years, leveraging T and NK cell immunology, maintaining innovation and a collaborative culture

2023-07-11, 12:45 PM

View In Agenda
Next speaker
Back
ESTHER MAHILLO
Vice President, Operational Strategy, Precision For Medicine

Dr. Mahillo has 28+ years of experience in the clinical research arena, 25 of them in oncology global trials. Her areas of expertise are inmuno-oncology, including cancer vaccines, advanced therapies, genetically modified organisms and other immuno therapies. She has an in-depth knowledge on oncology networks and advocacy groups, with which she cooperates since 1999. Dr. Mahillo is a professor/magister in several Master programs administered at different Universities (Universidad Alcalá de Henares, Universidad CEU San Pablo, CESIF). She has authored of 3 books, 20 scientific articles, and 24 contributions to scientific congresses. Dr. Mahillo was awarded the first prize of the Spanish Society of Medical Oncology (SEOM) in 2015 for her project “Y Seguiré” (will keep on moving), for the promotion of clinical research. Dr. Mahillo obtained her PhD with a research on the role of multicatalytic proteinase (proteasome) as an oncology intracellular target, research line that ended up with the development of bortezomib, a proteasome inhibitor approved for the treatment of multiple myeloma patients.

Session Details:

Integrative approach to biomarker-driven patient enrolment in oncology and rare diseases clinical research

2023-07-11, 2:45 PM

View In Agenda
Next speaker
Back
KELLY FRANCHETTI
Senior Vice President And Global Head, Patient Insights And Strategy, YPrime

Kelly Franchetti is a Sr. Vice President and Global Head of Patient Insights and Strategy at YPrime. A highly experienced registered nurse who continues to spend time with patients directly, her diverse background comprises patient advocacy and clinical research. Kelly has over 25 years of experience in obtaining and discerning the patient and caregiver experience as well as developing strong relationships with advocacy groups on a global scale. She has extensive experience in multiple therapeutic areas such as oncology, cardiovascular, endocrinology, orthopedics, infectious disease, neurology, pediatrics, and critical care. This depth and breadth of experience translate into a keen understanding of how patients think regarding their treatment giving her a singular perspective on the best way to approach patients with their treatment options, and an understanding that proves invaluable to her pharmaceutical and clinical research stakeholders.

Session Details:

Advancing Technology in Oncology Clinical Trials and What the Patients Want You to Know

2023-07-12, 2:00 PM

View In Agenda
Next speaker

2022 Sponsors

Select a sponsor to learn more

Featured Sponsors

Session Sponsors

Technology Spotlight Sponsor

Exhibitors

Co-Sponsors

Media Centre

Media Partners

Become A Media Partner

A fantastic network of your peers and colleagues!

 

Clinical Operations in Oncology is the meeting place for leading pharmaceutical companies and biotechnology institutes. Discover how to excel in oncology operations and clinical supply strategy as well as form key connections for long-term success for your clinical trial.

See What It's All About

Press releases

  • 14 May -Clinical Operations In Oncology Trials Press release

    Download download press release

Enquiry

Contact Us

SPONSORSHIP ENQUIRIES

Conor Taylor

Sponsorship Sales Manager

+44 (0) 20 7936 6870

SPEAKING OPPORTUNITIES

Douglas Webber

Programme Director

+44 (0) 20 7866 9411

MARKETING ENQUIRIES

Moona Popal

Marketing Manager

+44 (0) 20 7936 6656

Sponsorship Enquiries

To enquire about sponsorship opportunities for the conference, please contact:

 

Conor Taylor

Sponsorship Sales Manager


+44 (0) 20 7936 6870

Speaker Enquiries

To enquire about speaking opportunities for the conference, please contact:

 

Douglas Webber

Programme Director


+44 (0) 20 7866 9411